Harrow, Inc. (NASDAQ:HROW) Q3 2023 Earnings Conference Call November 13, 2023 4:45 PM ET Corporate Participants Jamie Webb - Director-Communications & Investor Relations Mark Baum - Chief Executive Officer Andrew Boll - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann Mayank Mamtani - B. Riley Operator Good afternoon, and welcome to Harrow's Third Quarter 2023 Earnings Conference Call. My name is Betsy, and I will be your ope ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission File Number: 001-35814 Harrow, Inc. (Exact name of registrant as specified in its charter) Delaware 45-0567010 (State or othe ...

H A R R O W * Your patients. Our purpose. Poised to become a top-tier U.S. ophthalmic pharmaceutical company. o Service 4,000+ monthly accounts of over 10,000 prescribers and institutions. Management utilizes Adjusted EBITDA, an unaudited financial measure that is not calculated in accordance with GAAP, to evaluate the Company's financial results and performance and to plan and forecast future periods. Investors are encouraged to review the Company's complete results of operations and additional information ...

Harrow Health, Inc. (NASDAQ:HROW) Q2 2023 Earnings Conference Call August 9, 2023 4:45 PM ET Company Participants Jamie Webb - Director-Communications & Investor Relations Mark L. Baum - Chief Executive Officer & Chairman-Board of Directors Andrew Boll - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Brooks O'Neil - Lake Street Capital Markets Mayank Mamtani - B. Riley Jim Roumell - Roumell Asset Management Operator Good afternoon, and welcome to Harrow's Second Quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name on exchange on which registered | | --- ...

Harrow Health, Inc. (NASDAQ:HROW) Q1 2023 Earnings Conference Call May 11, 2023 4:45 PM ET Company Participants Jamie Webb - Director, Communications and Investor Relations Mark Baum - Chief Executive Officer Andrew Boll - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Mayank Mamtani - B. Riley Securities Brooks O'Neil - Lake Street Capital Markets Operator Good afternoon, and welcome to Harrow's First Quarter 2023 Earnings Conference Call. My name is Joe, and I will ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission File Number: 001-35814 Harrow Health, Inc. (Exact name of registrant as specified in its charter) Delaware 45-0567010 (State or othe ...

Harrow Health, Inc. (NASDAQ:HROW) Q4 2022 Earnings Conference Call March 23, 2023 4:45 PM ET Company Participants Jamie Webb - Director, Communications and IR Mark Baum - Chief Executive Officer Andrew Boll - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Sahil Kazmi - B. Riley Securities Operator Good afternoon. And welcome to Harrow’s Q4 2022 Earnings Conference Call. My name is MJ, and I will be your operator for today’s call. At this time, all participan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 45-0567010 (State or other jurisdiction of ...

Letter to Stockholders November 14, 2022 Dear Harrow Stockholders: I am pleased to report third quarter results that included 22% year-over-year revenue growth and the company remaining "in the black" while we prepare to launch IHEEZO™, generate new high-value revenues from our portfolio of FDA-approved branded pharmaceutical products (BPPs), and advance our market-leading ImprimisRx compounded pharmaceuticals products (CPPs) brand. Here are a few recent noteworthy events connected to the continued executio ...